Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omecaxone sodium
- Development stage
- Unknown
- Lead developer
- Hangzhou Aomuo Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Omecaxone sodium (Aom0498) is a selective relaxant binding agent (SRBA) developed by Hangzhou Aomuo Pharmaceutical and Zhejiang Xianju Pharmaceutical. It is a modified cyclodextrin derivative designed to reverse neuromuscular blockade induced by aminosteroid non-depolarizing agents, specifically rocuronium and vecuronium. Similar in mechanism to sugammadex, omecaxone sodium acts by encapsulating the neuromuscular blocking agent (NMBA) molecules in the plasma in a 1:1 ratio. This sequestration prevents the NMBAs from binding to nicotinic acetylcholine receptors at the neuromuscular junction, leading to a rapid and predictable reversal of muscle relaxation. The drug has been evaluated in Phase II clinical trials in China for the reversal of deep rocuronium-induced neuromuscular blockade during elective surgery.
- Other names
- omecamtiv sodiumOmecaxone sodium奥美加松钠
02
Targets
β-cardiac myosin S1 domain
Beyond the preview
Go deeper on omecaxone sodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omecaxone sodium.